PH12022551151A1 - Anti-varicella-zoster virus antibody - Google Patents
Anti-varicella-zoster virus antibodyInfo
- Publication number
- PH12022551151A1 PH12022551151A1 PH1/2022/551151A PH12022551151A PH12022551151A1 PH 12022551151 A1 PH12022551151 A1 PH 12022551151A1 PH 12022551151 A PH12022551151 A PH 12022551151A PH 12022551151 A1 PH12022551151 A1 PH 12022551151A1
- Authority
- PH
- Philippines
- Prior art keywords
- varicella
- zoster virus
- virus antibody
- antibody
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/04—Varicella-zoster virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911095151.9A CN112778413B (zh) | 2019-11-11 | 2019-11-11 | 抗水痘-带状疱疹病毒的抗体 |
| PCT/CN2020/126159 WO2021093639A1 (zh) | 2019-11-11 | 2020-11-03 | 抗水痘-带状疱疹病毒的抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551151A1 true PH12022551151A1 (en) | 2023-10-02 |
Family
ID=75749734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551151A PH12022551151A1 (en) | 2019-11-11 | 2020-11-03 | Anti-varicella-zoster virus antibody |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12491386B2 (enExample) |
| EP (1) | EP4063383A4 (enExample) |
| JP (1) | JP7689955B2 (enExample) |
| CN (5) | CN117106070B (enExample) |
| PH (1) | PH12022551151A1 (enExample) |
| WO (1) | WO2021093639A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117106070B (zh) * | 2019-11-11 | 2024-06-11 | 珠海泰诺麦博制药股份有限公司 | 抗水痘-带状疱疹病毒的抗体 |
| CN117683121B (zh) * | 2024-01-30 | 2024-04-16 | 北京百普赛斯生物科技股份有限公司 | 抗水痘-带状疱疹病毒抗体及其应用 |
| CN119192349A (zh) * | 2024-07-18 | 2024-12-27 | 北京市延庆区疾病预防控制中心 | 用于检测黄连素抗性病毒的试剂及方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2652959B2 (ja) * | 1987-12-15 | 1997-09-10 | 東燃料株式会社 | 水痘・帯状疱疹ウイルス感染症の検出薬及び検出方法 |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| WO1995031546A1 (en) | 1994-04-28 | 1995-11-23 | Scotgen Biopharmaceuticals, Inc. | Recombinant human anti-varicella zoster virus antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6528066B1 (en) * | 1999-09-14 | 2003-03-04 | University Of Iowa Research Foundation | Variant varicella-zoster viruses and methods of use |
| BRPI0807084A2 (pt) * | 2007-02-06 | 2014-04-29 | Ribovax Biotechnologies Sa | Anticorpos específicos para o virus varicela zoster |
| CN102517302A (zh) * | 2011-12-28 | 2012-06-27 | 中国人民解放军军事医学科学院野战输血研究所 | 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用 |
| CN104513813A (zh) * | 2013-09-29 | 2015-04-15 | 上海满益科技有限公司 | 一种带状疱疹病毒的制备方法 |
| KR101481362B1 (ko) * | 2014-01-28 | 2015-01-15 | 연세대학교 원주산학협력단 | 수두대상포진 바이러스의 당단백질e를 발현하는 인간 세포를 이용한 수두대상포진 바이러스에 대한 면역력 진단 방법 |
| CN105669838B (zh) * | 2014-12-04 | 2020-10-16 | 厦门大学 | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 |
| JP6367783B2 (ja) * | 2015-11-26 | 2018-08-01 | 田中貴金属工業株式会社 | 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置 |
| CN106279378B (zh) * | 2016-08-05 | 2018-06-19 | 北京市华信行生物科技有限公司 | 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途 |
| KR102028463B1 (ko) * | 2016-11-25 | 2019-10-04 | 재단법인 목암생명과학연구소 | 바리셀라 조스터 바이러스 백신 |
| CN107760690B (zh) * | 2017-10-25 | 2018-08-28 | 珠海泰诺麦博生物技术有限公司 | 一种高通量全人源抗体的制备方法及应用 |
| US11147870B2 (en) * | 2018-04-25 | 2021-10-19 | Emory University | Specific binding agents to varicella-zoster virus and uses related thereto |
| CN109085354B (zh) * | 2018-07-25 | 2021-07-23 | 武汉生命科技股份有限公司 | 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 |
| CN117106070B (zh) * | 2019-11-11 | 2024-06-11 | 珠海泰诺麦博制药股份有限公司 | 抗水痘-带状疱疹病毒的抗体 |
-
2019
- 2019-11-11 CN CN202311089088.4A patent/CN117106070B/zh active Active
- 2019-11-11 CN CN202311088952.9A patent/CN117106068B/zh active Active
- 2019-11-11 CN CN202311089485.1A patent/CN117106071B/zh active Active
- 2019-11-11 CN CN202311089024.4A patent/CN117106069B/zh active Active
- 2019-11-11 CN CN201911095151.9A patent/CN112778413B/zh active Active
-
2020
- 2020-11-03 US US17/775,727 patent/US12491386B2/en active Active
- 2020-11-03 PH PH1/2022/551151A patent/PH12022551151A1/en unknown
- 2020-11-03 JP JP2022526794A patent/JP7689955B2/ja active Active
- 2020-11-03 EP EP20887206.9A patent/EP4063383A4/en active Pending
- 2020-11-03 WO PCT/CN2020/126159 patent/WO2021093639A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN117106070B (zh) | 2024-06-11 |
| CN117106070A (zh) | 2023-11-24 |
| EP4063383A4 (en) | 2024-01-17 |
| CN117106069A (zh) | 2023-11-24 |
| US12491386B2 (en) | 2025-12-09 |
| CN117106071A (zh) | 2023-11-24 |
| CN112778413B (zh) | 2023-09-22 |
| CN117106071B (zh) | 2024-08-27 |
| EP4063383A1 (en) | 2022-09-28 |
| JP2023500387A (ja) | 2023-01-05 |
| CN117106068B (zh) | 2024-04-16 |
| CN112778413A (zh) | 2021-05-11 |
| WO2021093639A1 (zh) | 2021-05-20 |
| JP7689955B2 (ja) | 2025-06-09 |
| US20230192817A1 (en) | 2023-06-22 |
| CN117106069B (zh) | 2024-06-11 |
| CN117106068A (zh) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500859A1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| EP4435009A3 (en) | Claudin6 antibodies and methods of treating cancer | |
| IN2012DN01328A (enExample) | ||
| FI3334763T3 (fi) | Uusia pd-l1-vasta-aineita | |
| GEAP202114794A (en) | Antibody neutralizing human respiratory syncytial virus | |
| PH12016501120B1 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| BR112018006579A2 (pt) | anticorpos anti-humanos cd19 humanizados e métodos de uso | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| NZ727024A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| MA40913A (fr) | Conjugués anticorps-médicament | |
| JP2013198490A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| PH12022551151A1 (en) | Anti-varicella-zoster virus antibody | |
| SG10201806025TA (en) | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| MX2020008122A (es) | Anticuerpos anti-pd-1. | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| WO2020139175A3 (ru) | Моноклональные антитела против участка бета-цепи trbv9 человека | |
| ZA201806397B (en) | Humanized anti clever-1 antibodies and their use | |
| PH12021551535A1 (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| EA201300131A1 (ru) | Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use |